Ontology highlight
ABSTRACT:
SUBMITTER: Dietrich B
PROVIDER: S-EPMC7091414 | biostudies-literature | 2013 Nov
REPOSITORIES: biostudies-literature
Dietrich Barbara B Schiviz Alexandra A Hoellriegl Werner W Horling Frank F Benamara Karima K Rottensteiner Hanspeter H Turecek Peter L PL Schwarz Hans Peter HP Scheiflinger Friedrich F Muchitsch Eva-Maria EM
International journal of hematology 20130924 5
Baxter has developed a new recombinant factor IX (rFIX) drug product (BAX326) for treating patients with hemophilia B, or congenital FIX deficiency. An extensive preclinical program evaluated the pharmacokinetics, efficacy, and safety of BAX326 in different species. The efficacy of BAX326 was tested in three mouse models of primary pharmacodynamics: tail-tip bleeding, carotid occlusion, and thrombelastography. The pharmacokinetics was evaluated after a single intravenous bolus injection in mice, ...[more]